AMEG

Actinomycetes are a well-known and very intensively examined group of bacteria. They have produced various antibiotics and antitumor drugs and are industrially used to produce antibiotics and agro chemicals. Despite them being thoroughly studied, a huge potential remains still to be revealed. Recent DNA deciphering efforts, where the entire genomes of actinomycetes have been sequenced, revealed that these bacteria remained a very rich source of new potentially active natural products.
   Hence, a huge reservoir of bioactive molecules stays “hidden” in the numerous publicly available bacterial genomes and metagenomes, confirming the strong limitations of conventional approaches for novel drug discovery.
   Therefore, the major challenge in the field is exploitation of this untapped genomic potential, and its conversion into bioactive chemical entities for their further development as drugs.
   In our department we aim to apply a synthetic biology approaches and to develop a truly functional technology platform for discovery, bioengineering and sustainable supply those hidden in genomes compounds for pharmacological testing.